September 29th 2023
Benefits of exogenous hormone use, as well as data indicating no association with increased breast cancer risk, were discussed at The Menopause Society 2023 Annual Meeting.
23rd Annual International Congress on the Future of Breast Cancer® East
Register Now!
Clinical ConsultationsTM: Focusing on Fabry Disease in Females: Individualizing Diagnostic and Counseling Plans to Improve Long-Term Outcomes
View More
Reflective Case-Based Oncology Collective: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
5th Annual Precision Medicine Symposium: An Illustrated Tumor Board
Register Now!
7th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)
Register Now!
Expanding Options Beyond Conventional Therapy in HR+ Breast Cancer to Overcome Unmet Needs
View More
21st Annual School of Breast Oncology
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow®
Register Now!
Clinical Conversations With the Cancer Care Team: Discussing the Impact of Social Inequities on Treatment Outcomes in Triple-Negative Breast Cancer
View More
Community Practice Connections™: Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
View More
Burst CME™ - Part III – Advent of HER3 Targeted Approaches and Rationale in Breast Cancer Care
View More
Burst CME™ - Part I – Overview of Pathophysiology, Diagnosis, and Management of HER3 Expressing Cancers
View More
Burst CME™ - Part II – Advent of HER3 Targeted Approaches and Rationale in NSCLC Care
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
Advances In™: Meeting Unmet Clinical Needs in TNBC and HR+ Breast Cancer with TROP2-Targeted Regimens
View More
Medical Crossfire®: Clinical Decision-Making Under New Paradigms for HR+/HER2- Breast Cancer
View More
Oncology Consultations®: Clinical Impact of HER2-Low Expressing Breast Cancer and Novel Targeted Therapies to Address Unmet Needs in Care
View More
Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow
View More
BURST CME™: Addressing Current Standards and Unmet Needs in Patients with Metastatic Breast Cancer
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates From San Antonio
View More
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
View More
Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care
View More
Community Practice Connections™: Clinical Decision Making Under New Paradigms for HR+/HER2-Breast Cancer
View More
School of Breast Oncology
View More
41st Annual Miami Breast Cancer Conference®
Register Now!
Patient, Provider, & Caregiver Connection: Individualizing Care in Multiple Sclerosis – Understanding Patient Challenges and the Role of Innovative Treatment
View More
Optimizing Pain Management for Breast Cancer Surgery Patients in the Age of the Opioid Epidemic
View More
Identifying and Mitigating Disparities in Breast Cancer Care: Improving Diagnostics, Trial Access and Care for All Patients
View More
Medical Crossfire®: Optimizing Treatment Sequencing for HR+/HER2- Metastatic Breast Cancer Based on Emerging Evidence and Evolving Algorithms
View More
Expert Illustrations & Commentaries™: Targeting Immune Cells to Treat Multiple Sclerosis
View More
Data aid in treatment for vulvovaginal health, sexual function after cancer
October 11th 2021Analyzing the relationship between data from patient self-reports and clinician ratings of vulvovaginal tissue health following cancer can help provide better sexual function treatment for patients, according to a recent study.
Read More
FDA grants trastuzumab deruxtecan breakthrough therapy designation for breast cancer
October 5th 2021The designation was based on data from the DESTINY-Breast03 phase 3 trial, and this is now the second BTD for trastuzumab deruxtecan in breast cancer, bringing its total number of BTDs to 4, according to an AstraZeneca press release.
Read More
Breast cancer and cervical cancer screenings on the decline
August 2nd 2021According to data from the Centers for Disease Control’s (CDC) National Breast and Cervical Cancer Early Detection Program, the total number of cancer screening tests declined 87% for breast cancer and 84% for cervical cancer during April 2020.
Read More
Highlights from the 2020 San Antonio Breast Cancer Symposium
December 25th 2020Following the 2020 San Antonio Breast Cancer Symposium, Erika P. Hamilton, MD, and William J. Gradishar, MD, shared their key takeaways and insights from the most impactful data presented during this year’s meeting.
Read More
FDA safety alert: Efficacy concerns for a combination therapy in breast cancer treatment
September 16th 2020Officials from the Food and Drug Administration (FDA) issued a safety alert on Sept. 8 about potential efficacy and safety concerns with Tecentriq in combination with Paclitaxel for breast cancer treatment.
Read More
Insulin resistance contributes to racial disparities in breast cancer prognosis in US women
August 4th 2020The lack of data on the possible connection between race and breast cancer prognosis is what led a group of Mount Sinai researchers to conduct this new multicenter, cross-sectional study.
Read More